4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
IPO Year: 2020
Exchange: NASDAQ
Website: 4dmoleculartherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/13/2025 | $40.00 → $15.00 | Outperform → Market Perform | BMO Capital Markets |
| 11/21/2024 | $8.00 | Underweight | Morgan Stanley |
| 9/23/2024 | Overweight → Neutral | Cantor Fitzgerald | |
| 4/15/2024 | $45.00 | Overweight | Barclays |
| 4/15/2024 | $459.00 | Overweight | Barclays |
| 2/7/2024 | $81.00 | Buy | Goldman |
| 10/26/2023 | $25.00 | Outperform | RBC Capital Mkts |
| 10/24/2023 | $32.00 | Overweight | Cantor Fitzgerald |
| 10/18/2023 | $24.00 | Market Perform → Outperform | Leerink Partners |
| 7/5/2023 | $30.00 | Buy | Chardan Capital Markets |
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company's board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market f
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027RMAT designation received from FDA for 4D-150 in DME, adding to previous regulatory designations of RMAT and PRIME (EMA) for 4D-150 in wet AMD$458 million in cash, cash equivalents, and marketable securities as of March 31, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in May. Members of the management team will also be available for one-on-one meetings. BofA Securities 2025 Healthcare Conference Presentation Date:Wednesday, May 14, 2025Presentation Time:2:20 p.m. PTWebcast Link:Webcast RBC Capital Markets 2025 Global Healthcare Conference Presentatio
EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). "This milestone validates the potential of 4D-150 to address the significant unmet needs of patients with DME, a second large market retinal vascular disease indication after wet age-related
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025, the compensation committee of the Company's board of directors granted three new non-executive employees 16,500 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Marke
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings. RBC Capital Markets 2025 Ophthalmology Conference Presentation Date:Thursday, April 3, 2025Presentation Time:9:15 a.m. ETWebcast Link:
EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (wet AMD). "This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial," said David Kirn, M.D., Co-founder and Chief Executive Of
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability Announced positive interim 32-week data for 4D-150 in DME from Part 1 of SPECTRA clinical trial and alignment with FDA for a single Phase 3 trial being acceptable for the basis of BLA submission for 4D-150 in DME when combined with data generated from 4FRONT Phase 3 trials in wet AMD4FRONT Phase 3 program in wet AMD on track with initiation of 4FRONT-1 expected in March 2025 and 4FRONT-2 in Q3 2025, with topline data from both studies expected in 2H 20
EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings. Leerink's Global Biopharma Conference 2025 Presentation Date: Tuesday, March 11, 2025Presentation Time: 10:00 a.m. ETWebcast Link: Webcast Barclays Global Healthcare Conference 2025 Presentation Date: Wednesday, March 12, 2025Presentation Time: 10:00 a.m. ETWebc
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeksIn the recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and 4FRONT-2 patient populations, 87% required 0-1 supplemental injection and 80% were injection-free through 52 weeksDurable and stable aflibercept expression demonstrated across all 3E10 vg/eye PRISM cohorts, with up to two years of follow-up4D-150 continues to be well tolerated, with up to three years of follow-up4FRONT-1 and 4FRONT-2 are on target to initiate in Q1 and Q3 2025, respectively Company to host webcast on Monday, F
BMO Capital Markets downgraded 4D Molecular Therapeutics from Outperform to Market Perform and set a new price target of $15.00 from $40.00 previously
Morgan Stanley initiated coverage of 4D Molecular Therapeutics with a rating of Underweight and set a new price target of $8.00
Cantor Fitzgerald downgraded 4D Molecular Therapeutics from Overweight to Neutral
Barclays initiated coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $45.00
Barclays initiated coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $459.00
Goldman resumed coverage of 4D Molecular Therapeutics with a rating of Buy and set a new price target of $81.00
RBC Capital Mkts initiated coverage of 4D Molecular Therapeutics with a rating of Outperform and set a new price target of $25.00
Cantor Fitzgerald initiated coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $32.00
Leerink Partners upgraded 4D Molecular Therapeutics from Market Perform to Outperform and set a new price target of $24.00
Chardan Capital Markets initiated coverage of 4D Molecular Therapeutics with a rating of Buy and set a new price target of $30.00
SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
S-8 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
10-Q - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
DEFA14A - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
DEF 14A - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
EFFECT - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
POS AM - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
S-8 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
10-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
3 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)
Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical Affairs, Scientific Communications, Regulatory and Quality operations; most recently SVP & Chief Development Officer at Iveric Bio where he led development and approval of IZERVAYChristopher Simms named as Chief Commercial Officer, effective September 25, 2024; will oversee Pre-commercial and Commercial organizations, pre-launch preparations and development; most recently SVP & Chief Commercial Officer at Iveric Bio where he led commercial strategy and execution for the launch of IZERVAYCarlos Quezada-Ruiz, M.D., FASRS, named as SVP, Therapeutic Area Head, Ophthalmology; will lead t
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and cystic fibrosis (CF)Established next-generation AAV & CRISPR/Cas-based genetic medicines partnership for central nervous system (CNS) diseases with Arbor BiotechnologiesAnnounced organizational updates, including the appointment of UCSF Professor Noriyuki Kasahara (Nori), M.D., Ph.D. as Chief Scientific OfficerWell capitalized ending 2023 with $300 million in estimated cash, financial runway guidance unchanged and cash expected to be sufficient to fund operations into H1 2026 EMERYVILLE, Calif
EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT. Mr. Mehra will succeed August J. Moretti, J.D., who is retiring, and has agreed to serve in an advisory capacity to support Mr. Mehra's transition. Mr. Mehra will lead 4DMT's finance, business development, and precommercial functions and will be a member of 4DMT's Executive Team, reporting to David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. Mr. Mehr
EMERYVILLE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced the appointment of Noriyuki (‘Nori') Kasahara, MD, PhD to the Board of Directors. In addition, 4DMT announced the promotion of Fred Kamal, PhD to President and Chief Operating Officer, marking an expansion of the breadth and responsibility of Dr. Kamal's role as a member of the senior leadership team. "Together with our Executive Chairman, John Milligan, I am thrilled to welcome Nori to our Board as we continue to advance each of our five product candidates in clin
EMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies announced that Professor David Schaffer, Ph.D. has resigned as a director of 4D Molecular Therapeutics. Professor Schaffer's transition coincides with the evolution of 4DMT into a clinical-stage gene therapy company with five products in clinical development and plans to develop pre-commercial and late-stage clinical-regulatory capabilities, in addition to our on-going internal vector invention and GMP manufacturing platforms. Professor Schaffer was recently appointed Director of Califo
SAN DIEGO and BASEL, Switzerland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors. Dr. Chacko currently serves as President, CEO and member of the Board of Directors of ORIC Pharmaceuticals, Inc., (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. "Jacob is an accomplished life-science executive and highly regarded board member with a track record of building leading oncology-focused biotech
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of PennsylvaniaAnnounces sCFH as payload for 4D-175 lead product candidate for geographic atrophy (GA); sCFH extensively characterized in 3 genetic mouse models and in non-human primates (NHP)CFH variants with reduced complement inhibitory function are a well-validated genetic risk factor for GA secondary to age-related macular degeneration (AMD), with approximately 75% of AMD patients carrying a high-risk variant of CFH; utilizing a precision medicine approach, this population represents a potential target population for 4D-175Continues expans
All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and widespread transgene expression within ~50% of cardiomyocytes Engaging with FDA to lift clinical hold and resume enrollment with updated exclusion criteria and highly effective rituximab/sirolimus immunosuppressive regimen to reduce risk of atypical hemolytic uremic syndrome ("aHUS")Otherwise, generally well-tolerated with no liver, heart, or dorsal root ganglia ("DRG") toxicity observedCompany to host live webcast today at 4:30 p.m. EST EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 4D Mo
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection rate of ~11Following intravitreal 4D-150, Cohort 1 patients' annualized anti-VEGF injection rate was reduced by 96.7%80% of Cohort 1 patients had not received any supplemental aflibercept injections for up to ~10 months after 4D-150 dosingCohort 1 safety and tolerability of 4D-150 demonstrated to date, with no clinically significant intraocular inflammation or hypotony reportedConference call & webcast to be held Monday November 14, 2022 at 8:00 AM E.T. EMERYVILLE, Calif.
EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that enrollment has been completed in all 3 cohorts of the Phase 1 Dose Exploration stage of the Phase 1/2 clinical trial of intravitreal 4D-150 in patients with wet AMD (n=15 patients total; 5 patients per cohort). All 3 cohorts have been cleared for safety, with no dose-limiting toxicities (DLTs) being reported. 4D Molecular Therapeutics also announced that interim clinical data from cohort 1 of this Phase 1/2 clinical trial will be released at 7:30 am E.T., on
Cohort 1 lung bronchoscopy sample results demonstrate widespread delivery and expression of the 4D-710 CFTR∆R transgene in 100% of samples from all three patients Cohort 1 safety and tolerability of 4D-710 demonstrated to date, with no drug-related adverse events following aerosol deliveryCohort 1 enrollment completed; Cohort 2 enrollment on-goingConference call & webcast to be held today at 1:30 p.m. PT EMERYVILLE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinica
EMERYVILLE, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 will be presented during a symposium at the upcoming North American Cystic Fibrosis Conference (NACFC), being held November 3-5, 2022. The presentation will include a summary of 4D-710 safety, tolerability, delivery and CFTR transgene expression in patients with cystic fibrosis who have been enrolled on cohort 1 of the dose exploration portion of the clinical trial (n=3; 1E15 vg). NACFC Oral Pres
- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution - AGA enzyme activity was within, or significantly above, the normal range in all three patients (up to 25-fold mean normal AGA activity) - 4D-310 had a manageable safety profile and no dose-limiting toxicities - 4D-110 was generally well-tolerated, with initial evidence of clinical activity observed - 4DMT to host conference call and webcast on Monday, October 25, 2021 at 2:00 p.m PDT EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT), a clini
4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammationClinical activity observed through anatomical measurements of reduced photoreceptor loss in treated vs untreated control eyes on ellipsoid zone area endpointsClinical activity observed through functional improvements in treated vs untreated control eyes on two microperimetry endpoints: (1) mean retinal sensitivity and (2) number of loci with >7 dB improvement4DMT plans to continue enrollment at the 1E12 vg/eye in the dose expansion cohort, including in less advanced patients4DMT to host conference call and webcast on Monday, October 11, 2021
EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second quarter of 2021, and provided operational highlights. "Harnessing the power of directed evolution to develop targeted gene therapies is central to 4DMT, and this past quarter we continued to make substantial progress towards our goal," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. "Importantly, we initiated the expansion of our cGMP manufacturing facilities to support commercial-scale production of our clinical product
EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first quarter of 2021, and provided operational highlights. "We continue to relentlessly execute and innovate as demonstrated by achievements in our first full quarter as a public company," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. "The company remains on track to announce initial clinical data from both our 4D-310 Fabry disease product candidate and our 4D-125 XLRP product candidate in the second half of this year. In addit